INmune Bio Inc. to Report Third Quarter 2025 Financial Results

INmune Bio Inc. (NASDAQ: INMB) announced that it will host a conference call on October 30, 2025, at 4:30 PM Eastern Time to discuss its third quarter 2025 financial results and provide a corporate update. The call will be accessible via dial-in or webcast, with a transcript and replay available afterward. INmune Bio is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The company has three product platforms: DN-TNF, CORDStrom™, and INKmune®, which are in various stages of clinical trials. The press release also includes forward-looking statements regarding the company's product development and regulatory approval processes.